Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News Can Piramal Pharma Solutions’ ADCelerate platform gain an edge with IntoCell’s linker-payload tech? Piramal Pharma Solutions teams up with IntoCell to expand ADCelerate platform and access cutting-edge linker-payload tech. Explore how this reshapes the CDMO landscape. byPallavi MadhirajuOctober 30, 2025